From SNTA Q3 Cc " Iman El-Hariry (Phd) - Vice President of Clinical Research
" I think I also look at my plus 20 years or 15 years of industry experience and working in large pharma. Seeing a single agent activity -- and it's not an end of 1 or end of 2 that we have actually a very good number of single agent activity in different tumor size, including lung cancer, breast and others. It's been very encouraging. And it really is in line with the science that we started to become very conversant with on the HSD science and the incubation of client proteins, so when we took to our investigators specifically in breast cancer, there is huge interest in taking this drug in all subtests for instances in breast cancer. And given the level of evidence that, and the level of activity that we are seeing. So this is really very encouraging. I mean, like Ilker, I also worked on drugs that were approved and came to the market and comparing these with my past experience, I think the level of activity that I am seeing far exceeds that what I have seen in my past experience in any of the drugs that I also have taken to the market."